Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3655- SIL,    Protective effect of silymarin on oxidative stress in rat brain
- in-vivo, AD, NA
*GSH↑, *VitC↑, *SOD↑, *lipid-P↓, *ROS↓, *hepatoP↑, *neuroP↑,
3654- SIL,    Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain
- in-vivo, AD, NA
*ROS↓, *neuroP↑, *GSH↑, *SOD↑,
3653- SIL,    Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress
- in-vivo, AD, NA
*hepatoP↑, *neuroP↑, *cognitive↑, *memory↑, *Inflam↓, *GSH↑, *MDA↓, *Inflam↓, *antiOx↓,
3652- SIL,    Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus
- in-vivo, NA, NA
*hepatoP↑, *other↑,
3651- SIL,    Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
- Trial, NA, NA
*hepatoP↑, *ALAT↓,
3650- SIL,    Silibinin: a novel inhibitor of Aβ aggregation
- in-vitro, AD, SH-SY5Y
*Aβ↓, *H2O2↓,
3649- SIL,    Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis
*Inflam↓, *NF-kB↓, *cJun↓, *Casp↓, *ROS↓, *lipid-P↓,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3300- SIL,    Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy
- Review, Var, NA
*ROS↓, *SOD↑, *hepatoP↑, *AST↓, *ALAT↓, *lipid-P↓, *GSH↑, *Catalase↑, *GSTs↑, *GSR↑, *TNF-α↓, *IFN-γ↓, *IL4↓, *IL2↓, *NF-kB↓, *IL10↑, *Inflam↓, COX2↓, Apoptosis↑, ChemoSen↑, PGE2↓, VEGF↓,
3312- SIL,    Silymarin Alleviates Oxidative Stress and Inflammation Induced by UV and Air Pollution in Human Epidermis and Activates β-Endorphin Release through Cannabinoid Receptor Type 2
- Human, Nor, NA
*antiOx↑, *Inflam↓, *ROS↓, *IL1α↓, *AhR↑, *NRF2↑, *IL8↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3302- SIL,    Protective effects of silymarin in glioblastoma cancer cells through redox system regulation
- in-vitro, GBM, U87MG
NRF2↑, HO-1↑, Trx↑, antiOx↑,
3303- SIL,    Exploring the anti-cancer and antimetastatic effect of Silymarin against lung cancer
- Review, Var, NA
chemoP↑, radioP↑,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3307- SIL,    Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications
- Review, Var, NA
*NRF2↑, *antiOx↑, *chemoP↑, *Inflam↓, *BioAv↑, eff↑, *NQO1↑, TNF-α↓, IL6↓, *GSH↑, *ROS↓, *MDA↓, eff↑, *hepatoP↑, *GPx↑, *SOD↑, *Catalase↑, *HO-1↑, *neuroP↑,
3308- SIL,    Structural basis of Nrf2 activation by flavonolignans from silymarin
- Analysis, NA, NA
*antiOx↑, *chemoP↑, *NRF2↑,
3309- SIL,    Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
- Review, NA, NA
*ROS↓, *IronCh↑, *MMP↑, *NRF2↑, *Inflam↓, *hepatoP↑, *HSPs↑, *Trx↑, *SIRT2↑, *GSH↑, *ROS↑, *NADPH↓, *iNOS↓, *NF-kB↓, *BioAv↓, *Dose↝, *BioAv↑,
3310- SIL,    Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro
- in-vitro, Lung, A549
Inflam↓, MPO↓, NO↓, iNOS↓, ROS↓, MDA↑, SOD↑, Catalase↑, GPx↑, NRF2↑, HO-1↑, NADPH↑,
3311- SIL,    Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells
- in-vitro, Nor, PC12
*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,
3299- SIL,    Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells
- in-vitro, Colon, HT29
tumCV↓, MMP↓, ROS↑, selectivity↑,
3298- SIL,    Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells
- in-vitro, BC, MCF-7
LC3II↑, Beclin-1↑, Bcl-2↓, ROS↑, MMP↓, ATP↓, eff↓, BNIP3?, TumAuto↑, eff↑,
3297- SIL,  Rad,    Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells
- in-vitro, CRC, HCT15 - in-vitro, CRC, RKO
TumCP↓, RadioS↑, TumCCA↑, DNAdam↓, MMP↓, ROS↓, *radioP↑,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3295- SIL,    Hepatoprotective effect of silymarin
- Review, NA, NA
*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,
3294- SIL,    Silymarin: a review on paving the way towards promising pharmacological agent
- Review, Nor, NA - Review, Arthritis, NA
*hepatoP↑, *Inflam↓, *chemoP↑, *glucose↓, *antiOx↑, *ROS↓, *ACC↓, *FASN↓, *radioP↑, *NF-kB↓, *TGF-β↓, *AST↓, *α-SMA↝, *eff↑, *neuroP↑, eff↑, ROS↓,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3292- SIL,  Fe,    Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
*antiOx↑, ROS↑, OS↑, Weight↑, TumVol↓, eff↑, Fenton↑,
3291- SIL,    Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases
- Review, Nor, NA
*antiOx↑, *ROS↓, *cardioP↑, *BioAv↓, *Half-Life↝, *other↑, IronCh↑,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
1316- SIL,  Chemo,    Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity
- Analysis, Var, NA
TumCCA↑, p42↓, P450↓, OATPs↓, chemoP↑, ChemoSen↑,
4206- SIL,    Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response
- in-vivo, NA, NA
*BDNF↑, *5HT↑, *antiOx↑, *IL6↓, *TNF-α↓, *Mood↑,
4205- SIL,    The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review
- Review, AD, NA
*BDNF↑, *5HT↑, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *IL6↓, *IL1β↓,
4207- SIL,    Silymarin sex-dependently improves cognitive functions and alters TNF-α, BDNF, and glutamate in the hippocampus of mice with mild traumatic brain injury
*TNF-α↓, *BDNF↑, *cognitive↑,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2306- SIL,  CUR,  RES,  EA,    Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment
- in-vitro, BC, MDA-MB-231
PKM2↓, Dose↝, Dose↝,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
4122- Silicon,    Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease
- Trial, AD, NA
*other↓, *other∅, *cognitive↑,
4123- Silicon,    The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders
- Review, AD, NA
*Aβ↓, *cognitive↝,

Showing Research Papers: 5151 to 5200 of 5929
Prev Page 104 of 119 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5929

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   CYP1A1↓, 1,   Fenton↑, 1,   GPx↑, 1,   GSH↓, 2,   GSH↑, 1,   H2O2↑, 1,   HO-1↑, 2,   lipid-P↓, 3,   MDA↑, 1,   MPO↓, 1,   NRF2↑, 2,   OXPHOS↑, 1,   ROS↓, 4,   ROS↑, 8,   mt-ROS↑, 1,   SOD↓, 1,   SOD↑, 1,   SOD1↓, 1,   SOD2↓, 1,   Trx↑, 1,   xCT↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 3,   MEK↓, 1,   p‑MEK↓, 1,   MMP↓, 7,   MMP↑, 1,   mtDam↑, 1,   p42↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   ALAT↓, 1,   i-citrate↑, 1,   cMyc↓, 4,   FASN↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   HK2↓, 2,   lactateProd↓, 2,   LDHA↓, 2,   NADPH↓, 1,   NADPH↑, 1,   PFKP↓, 1,   PKM2↓, 2,   PPP↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 3,   Akt↑, 1,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 8,   BAX↑, 7,   Bcl-2↓, 9,   Bcl-2↑, 1,   Bcl-xL↓, 3,   BID↑, 1,   BIM↓, 1,   Casp↑, 2,   Casp3↑, 8,   cl‑Casp3↑, 1,   pro‑Casp8↑, 1,   Casp9↑, 7,   Cyt‑c↑, 5,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 2,   p‑JNK↓, 1,   p‑JNK↑, 3,   MAPK↓, 3,   Mcl-1↓, 3,   p27↑, 2,   p‑p38↓, 2,   p‑p38↑, 2,   survivin↓, 6,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 2,   miR-21↓, 1,   p‑pRB↓, 1,   tumCV↓, 4,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3?, 1,   BNIP3↝, 1,   LC3II↑, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↓, 2,   DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 6,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 3,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK4↓, 2,   CDK4↑, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   P21↑, 3,   RB1↑, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 1,   EMT↓, 5,   ERK↓, 5,   p‑ERK↓, 5,   FOXM1↓, 1,   Gli1↓, 1,   HDAC↓, 2,   HH↓, 1,   IGFBP3↑, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 3,   STAT3↓, 6,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 7,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Akt2↓, 1,   AP-1↓, 2,   CA↓, 1,   Ca+2↑, 1,   CD31↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   GLI2↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 2,   MMP9↓, 4,   MMPs↓, 1,   N-cadherin↓, 2,   PDGF↓, 1,   RHBDD1↓, 1,   TGF-β↓, 2,   TumCI↓, 3,   TumCMig↓, 6,   TumCP↓, 8,   TumMeta↓, 3,   uPA↓, 2,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 7,   LOX1↓, 1,   NO↓, 1,   VEGF↓, 5,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   NHE1↓, 1,   OATPs↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   CXCR4↓, 3,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↓, 2,   IL10↓, 1,   IL1β↓, 2,   IL2↑, 1,   IL6↓, 2,   Inflam↓, 7,   JAK2↓, 1,   MDSCs↓, 1,   NF-kB↓, 5,   PD-L1↓, 2,   PGE2↓, 3,   PSA↓, 2,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   ChemoSen↑, 2,   Dose↝, 5,   eff↓, 1,   eff↑, 11,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 2,   P450↓, 1,   RadioS↑, 2,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   EGFR↓, 2,   p‑EGFR↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 1,   PD-L1↓, 2,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 3,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 8,   hepatoP↑, 4,   neuroP↑, 1,   OS↑, 1,   radioP↑, 4,   Strength↑, 1,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 3,   Weight↑, 1,   Weight∅, 1,  
Total Targets: 224

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 12,   Catalase↑, 3,   GCLC↑, 1,   GCLM↑, 1,   GPx↑, 2,   GSH↓, 1,   GSH↑, 10,   GSR↑, 1,   GSTs↑, 2,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 6,   MDA↓, 4,   NQO1↑, 1,   NRF2↑, 5,   ROS↓, 13,   ROS↑, 1,   SOD↑, 7,   Trx↑, 2,   VitC↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   ALAT↓, 4,   FASN↓, 1,   glucose↓, 1,   NADPH↓, 1,   PPARγ↑, 1,   SIRT1↑, 2,   SIRT2↑, 1,  

Cell Death ⓘ

AhR↑, 1,   Casp↓, 1,   iNOS↓, 1,   JNK↑, 1,   necrosis↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   other↓, 1,   other↑, 2,   other∅, 1,  

Protein Folding & ER Stress ⓘ

HSP27↑, 1,   HSPs↓, 1,   HSPs↑, 1,  

Migration ⓘ

TGF-β↓, 1,   TIMP1↓, 1,   α-SMA↓, 1,   α-SMA↝, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT4↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 3,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL1α↓, 1,   IL1β↓, 1,   IL2↓, 1,   IL4↓, 2,   IL6↓, 3,   IL8↓, 2,   Inflam↓, 13,   NF-kB↓, 4,   TNF-α↓, 6,  

Synaptic & Neurotransmission ⓘ

5HT↑, 2,   BDNF↑, 3,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 3,   BioAv↝, 2,   Dose↝, 1,   eff↑, 1,   Half-Life↓, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 4,   AST↓, 3,   IL6↓, 3,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 3,   cognitive↑, 3,   cognitive↝, 1,   hepatoP↑, 12,   memory↑, 1,   Mood↑, 1,   neuroP↑, 5,   radioP↑, 2,   RenoP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 88

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page